Stifel Financial’s Cymabay Therapeutics CBAY Stock Holding History

Stifel Financial’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-13,500	Closed	-$179K	–	3066
2019 Q1	$179K	Buy	13,500 +1,500	+13%	+$16K	﹤0.01%	2617
2018 Q4	$96K	Sell	12,000 -3,500	-23%	-$33.3K	﹤0.01%	2566
2018 Q3	$172K	Hold	15,500	–	–	﹤0.01%	2617
2018 Q2	$207K	Sell	15,500 -7,500	-33%	-$93.9K	﹤0.01%	2535
2018 Q1	$297K	Buy	+23,000	New	+$286K	﹤0.01%	2261

Other funds holding CBAY

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Stifel Financial's CBAY Position: Q2 2019 in Review

Stifel Financial sold out of Cymabay Therapeutics (CBAY) in Q2 2019, closing a stake of 13,500 shares — an estimated $179K sold.

Stifel Financial first reported a position in CBAY in Q1 2018 and held it in 5 quarters. The position peaked at $297K in Q1 2018. 133 funds tracked by Wall St. Rank hold CBAY as of Q2 2019.

Stifel Financial reported no remaining Cymabay Therapeutics position as of Q2 2019 after selling out during the quarter.
Stifel Financial sold 13,500 Cymabay Therapeutics shares in Q2 2019, an estimated $179K.
Stifel Financial first reported a position in Cymabay Therapeutics in Q1 2018 and held it in 5 quarters.
Stifel Financial's Cymabay Therapeutics position peaked at $297K in Q1 2018.
133 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2019.

Based on Stifel Financial's 13F filing for Q2 2019, filed 14 Aug 2019.